Search results
Fatty Liver to Cirrhosis Timeline: Prevalence, Treatment, and Outlook
Healthline· 7 days agoIt usually takes years for fatty liver disease to progress to cirrhosis, but several factors affect...
Targeting bile acid pathways offers hope for liver disease treatment
Medical Xpress· 1 day agoBile acids are essential molecules the liver produces that play a critical role in digestion. They help us absorb fat-soluble vitamins and cholesterol from our food. However, bile acids can ...
Zealand Pharma says drug shows improvement in fatty liver disease patients
Reuters via AOL· 1 day agoThe company said the data from the trial in patients with metabolic dysfunction-associated steatohepatitis (MASH) was unintentionally and temporarily leaked ahead of its scheduled release on ...
High levels of novel biomarker GDF15 in steatotic liver patients linked to increased liver cancer...
Medical Xpress· 1 day agoThe findings are published in the journal Alimentary Pharmacology & Therapeutics. Steatotic (fatty) liver disease is on the rise in many countries around ...
...Madrigal In Favor Of Eli Lilly And Company's GLP-1 Agonist For The Treatment Of Fatty Liver ...
Wccftech· 2 days agoFor the benefit of those who might not be aware, MASH is a fatty liver disease that develops...
These 5 lifestyle changes improved brain function for those with early Alzheimer’s
Fortune via Yahoo Finance· 5 hours agoConnection: The participants and their spouses attended a one-hour group session with a mental...
Zealand Pharma Shares Jump After Drug Shows Promise in Liver Trial
Market Watch· 1 day agoZealand Pharma shares rose after a drug candidate being tested as a treatment for obesity showed positive results in a mid-stage clinical trial for a type of fatty ...
Boehringer Ingelheim's survodutide shows breakthrough improvement in liver fibrosis with no...
Benzinga· 14 hours agoNews builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo
Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?
Investor's Business Daily· 4 hours agoIn MASH, fatty tissue builds up on the liver, causing scar tissue called fibrosis. A drug must...
Researchers use spatial multi-omics to investigate liver zonation and role of GPR35 in disease...
Medical Xpress· 4 days agoMetabolic dysfunction-associated steatotic liver disease (MASLD), an escalating metabolic disorder, poses a severe challenge to global health. However, our understanding of its underlying molecular mechanisms remains limited.